Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search

Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

Profile Photo

Professor Paul Browne

Fellow Emeritus (Fellows Emeritii)


Townsend L, Dyer AH, Naughton A, Imangaliyev S, Dunne J, Kiersey R, Holden D, Mooney A, Leavy D, Ridge K, Sugrue J, Aldoseri M, Kelliher JH, Ní Cheallaigh C, Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression, Heliyon, 8, (4), 2022, pe09230 - e09236, Journal Article, PUBLISHED
Masouridi-Levrat S, Olavarria E, Iacobelli S, Aljurf M, Morozova E, Niittyvuopio R, Sengeloev H, Reményi P, Helbig G, Browne P, Ganser A, Nagler A, Snowden JA, Robin M, Passweg J, Van Gorkom G, Wallet HL, Hoek J, Blok HJ, De Witte T, Kroeger N, Hayden P, Chalandon Y, Agha IY., Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT., Bone marrow transplantation, 57, (1), 2022, p23-30 , Journal Article, PUBLISHED  DOI
O'Gorman P, Laubach JP, O'Dwyer ME, Krawczyk J, Yee AJ, Gilligan O, Cahill MR, Rosenblatt J, Quinn J, Murphy PT, DiPietro H, Perera MR, Crotty GM, Cummings K, Hayden PJ, Browne P, Savell A, O'Leary HM, O'Keeffe D, Masone K, Hennessy BJ, Guerrero Garcia T, Scott K, Saeed K, Bianchi G, Dowling P, Tierney C, Richardson PG., Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma., American journal of hematology, 97, (5), 2022, p562-573 , Journal Article, PUBLISHED  DOI
Waszczuk-Gajda A., Penack O., Sbianchi G., Koster L., Blaise D., Remenyi P., Russell N., Ljungman P., Trneny M., Mayer J., Iacobelli S., Kobbe G., Scheid C., Apperley J., Touzeau C., Lenhoff S., Jantunen E., Anagnostopoulos A., Paris L., Browne P., Thieblemont C., Schaap N., Sierra J., Yakoub-Agha I., Garderet L., Styczynski J., Schoemans H., Moiseev I., Duarte R.F., Peric Z., Montoto S., van Biezen A., Mikulska M., Aljurf M., Ruutu T., Kroger N., Morris C., Koenecke C., Schoenland S., Basak G.W., Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study, Journal of Clinical Medicine, 11, (12), 2022, Journal Article, PUBLISHED  DOI
Rebecca Amet, Viola Previtali, Helene B. Mihigo, Emily Sheridan, Sarah Brophy , Nadhim Kamil Hante, Maria Jose Santos-Martinez, Patrick J. Hayden, Paul V. Browne, Isabel Rozas, Anthony M. McElligott , Daniela M. Zisterer , A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma , Life Sciences, 290, 2022, Journal Article, PUBLISHED  TARA - Full Text  DOI
Schetelig J., Chevallier P., van Gelder M., Hoek J., Hermine O., Chakraverty R., Browne P., Milpied N., Malagola M., Socie G., Delgado J., Deconinck E., Damaj G., Maury S., Beelen D., Quoc S.N., Shankara P., Brecht A., Mayer J., Hunault-Berger M., Bittenbring J., Thieblemont C., Lepretre S., Baldauf H., de Wreede L.C., Tournilhac O., Yakoub-Agha I., Kroger N., Dreger P., Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party (Bone Marrow Transplantation, (2021), 56, 3, (605-613), 10.1038/s41409-020-01069-w), Bone Marrow Transplantation, 57, (2), 2022, p330-, Journal Article, PUBLISHED  DOI
Domingo-Domenech E., Duarte R.F., Boumedil A., Onida F., Gabriel I., Finel H., Arcese W., Browne P., Beelen D., Kobbe G., Veelken H., Arranz R., Greinix H., Lenhoff S., Poire X., Ribera J.M., Thompson J., Zuckerman T., Mufti G.J., Cortelezzi A., Olavarria E., Dreger P., Sureda A., Montoto S., Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, Bone Marrow Transplantation, 56, (6), 2021, p1391 - 1401, p1391-1401 , Journal Article, PUBLISHED  DOI
Bright S.A, Byrne A.J, Vandenberghe E, Browne P.V, McElligott A.M, Meegan M.J, Williams D.C, Selected nitrostyrene compounds demonstrate potent activity in chronic lymphocytic leukaemia cells, including those with poor prognostic markers, Oncology Reports, 41, (5), 2019, p3127 - 3136, Journal Article, PUBLISHED  DOI  URL
Kyriakou C, Boumendil A, Finel H, NN Norbert Schmit, Andersen N.S, Blaise D, Chevallier P, Browne P, Malladi R, Niederwieser D, Pagliuca A, Kroschinsky F, Montoto S, Dreger P, The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party, Biology of Blood and Marrow Transplantation, 25, (1), 2019, p86 - 93, Journal Article, PUBLISHED  TARA - Full Text  DOI  URL
Michallet, M. and Dreger, P. and Sobh, M. and Koster, L. and Hoek, J. and Boumendil, A. and Scheid, C. and Fox, C.P. and Wulf, G. and KrÃŒger, W. and van Gelder, M. and Corradini, P. and Russo, D. and Passweg, J. and Schoemans, H. and Bethge, W. and Schaap, N. and Cornelissen, J. and Browne, P. and Durakovic, N. and Muller, L. and Montoto, S. and Kroger, N. and Schetelig, J., Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia, Bone Marrow Transplantation, 2019, Notes: [cited By 0], Journal Article, PUBLISHED  DOI

Page 1 of 7